NHS to Offer Free Weight-Loss Injections to Over a Million Heart Attack and Stroke Risk Patients

NHS Greenlights Free Weight-Loss Jabs for High-Risk Heart Patients

More than one million people across England could soon receive free weight-loss injections through the NHS as part of a major new push to protect those at serious risk of heart attacks and strokes. Health watchdog NICE has approved the rollout of the anti-obesity drug Wegovy — also known as semaglutide — for patients who are overweight and already living with cardiovascular disease or serious circulatory conditions.

What Is Wegovy and How Does It Work?

Wegovy is a weekly self-administered injection that works by mimicking a naturally occurring hormone called GLP-1. This hormone signals to the brain that the body is full, effectively suppressing appetite and slowing the pace of digestion. The result is gradual but meaningful weight reduction, though researchers now believe the drug's benefits extend well beyond shedding pounds.

The medication is recommended for patients with a Body Mass Index (BMI) of 27 or above — a threshold that covers both the overweight and obese categories. Patients will be able to administer the drug themselves at home using a specially designed pen injector, making it a convenient option for long-term use.

Some users may experience side effects including nausea, bloating, or general digestive discomfort, particularly in the early stages of treatment.

A 20% Reduction in Heart Attack and Stroke Risk

Clinical trials involving tens of thousands of participants produced striking results. When taken alongside existing heart medications such as statins, Wegovy was associated with a 20% reduction in the likelihood of experiencing a further heart attack or stroke.

Perhaps even more significant was the timing of these benefits. Improvements in cardiovascular outcomes were observed early in the trial period — before participants had lost a substantial amount of weight. This strongly suggests that semaglutide acts directly on the heart and blood vessels, rather than reducing risk purely through weight loss alone.

Based on the best available evidence, experts estimate that the drug could help prevent disease in approximately seven out of every ten eligible cases.

Who Will Be Eligible?

The new guidance targets patients who have already suffered a heart attack, stroke, or who are living with peripheral arterial disease — a condition affecting blood circulation in the legs. Each year in the UK, around 100,000 people are admitted to hospital due to heart attacks, a further 100,000 experience a stroke, and approximately 350,000 people manage peripheral arterial disease on an ongoing basis.

Those who have already experienced one of these conditions carry a significantly elevated risk of future episodes, making preventative treatment all the more critical.

A GP or specialist will assess each patient individually to determine whether Wegovy is an appropriate addition to their existing treatment plan. Lifestyle guidance — including dietary improvements and regular physical activity — will also be prescribed alongside the injections.

Expert Reactions: Hope and Caution

Helen Knight of NICE welcomed the decision, saying: "The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke. Today's decision gives thousands of people in that situation an extra layer of protection."

Dr. Sonya Babu-Narayan of the British Heart Foundation echoed this optimism, expressing hope that the injections would be made available to all eligible patients as swiftly as possible.

However, not everyone is without reservation. Professor Robert Storey, a cardiovascular specialist at the University of Sheffield, raised concerns about the potential for GLP-1 drugs to reduce muscle mass alongside body fat. He recommended that patients engage in resistance training and other forms of physical activity to counteract this effect and preserve muscle strength during treatment.

Cost and Availability

NICE has confirmed that NHS England has reached a pricing agreement with Novo Nordisk, the pharmaceutical company behind Wegovy, ensuring that the treatment will be delivered in a cost-effective manner for the health service.

Currently, NHS access to Wegovy is restricted to a two-year period through specialist services, and researchers continue to study its long-term safety profile. Many healthcare professionals argue, however, that the treatment should ultimately be considered lifelong — particularly given the well-documented risk of weight regain once the medication is discontinued.